vVardis Holding, which sells proprietary non-invasive treatments for cavities, lowered the proposed deal size for its upcoming IPO on Thursday. The Zug, Switzerland-based company now plans to raise $188 million by offering 8.3 million shares at a price range...read more
Updated Monday, 11/9. Three sizable issuers are slated to list in the week ahead, though all eyes are on the year’s next potential mega IPO. Anthropic (ANT) could launch its highly anticipated IPO as early as Tuesday, which would position the AI giant ...read more
vVardis Holding, which sells proprietary non-invasive treatments for cavities, announced terms for its IPO on Friday. The Zug, Switzerland-based company plans to raise $214 million by offering 9.5 million shares at a price range of $21 to $24. At the midpoint...read more
Two biotechs priced IPOs this past week and more joined the pipeline, along with a billion-dollar data center developer, an emerging markets fintech, and a dental treatment company. Autoimmune biotech TRex Bio (TRXB) priced at the low end to raise $117...read more
Cavity treatment provider vVardis decreases shares offered by 13% ahead of $188 million US IPO
vVardis Holding, which sells proprietary non-invasive treatments for cavities, lowered the proposed deal size for its upcoming IPO on Thursday. The Zug, Switzerland-based company now plans to raise $188 million by offering 8.3 million shares at a price range...read more
US IPO Week Ahead: Dental tech vVardis and two biotechs on deck as Anthropic launch looms
Updated Monday, 11/9. Three sizable issuers are slated to list in the week ahead, though all eyes are on the year’s next potential mega IPO. Anthropic (ANT) could launch its highly anticipated IPO as early as Tuesday, which would position the AI giant ...read more
Cavity treatment provider vVardis sets terms for $214 million US IPO
vVardis Holding, which sells proprietary non-invasive treatments for cavities, announced terms for its IPO on Friday. The Zug, Switzerland-based company plans to raise $214 million by offering 9.5 million shares at a price range of $21 to $24. At the midpoint...read more
US IPO Weekly Recap: Biotech IPOs keep flowing as data center developer DayOne joins the pipeline
Two biotechs priced IPOs this past week and more joined the pipeline, along with a billion-dollar data center developer, an emerging markets fintech, and a dental treatment company. Autoimmune biotech TRex Bio (TRXB) priced at the low end to raise $117...read more